Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01203514 · ClinicalTrials.gov registry record · Phase 2
The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants
A Phase 2 study, sponsored by NICHD Neonatal Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 318
- Enrollment target
NCT01203514: Completed Phase 2 study, sponsored by NICHD Neonatal Research Network.
NCT01203514 is a Phase 2 study that has completed, run by NICHD Neonatal Research Network. The registered enrollment target is 318 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (139% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01203514, a Phase 2 study, has completed, sponsored by NICHD Neonatal Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 318 participants
- Enrollment target
Study Summary
This study tested the safety and efficacy of transfusing erythropoietin (Epo) and iron in infants of \<1,250g birth weight. For infants 401-1,000g birth weight, we tested whether early erythropoietin (Epo) and iron therapy would decrease the number of transfusions received. For infants 1,001-1,250g birth weight, we tested whether early erythropoietin (Epo) and iron therapy would decrease the percentage of infants who received any transfusions.
Interventions
- OTHER Sham Comparator
- DRUG Erythropoietin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 318 participants |
| Start Date | 1997-08 |
| Est. Completion | 2000-08 |
| Phase | Phase 2 |
What the finished NCT01203514 record still lists
NCT01203514 is an interventional study that assigns participants to a tested intervention. The registered 318 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (139% higher).
The record links to 0 conditions, and to 2 interventions - of which Sham Comparator is the first listed.
NCT01203514 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01203514 about?
NCT01203514 is a clinical study titled "The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants". This study tested the safety and efficacy of transfusing erythropoietin (Epo) and iron in infants of \<1,250g birth weight. For infants 401-1,000g birth weight, we tested whether early erythropoietin (Epo) and iron therapy would decrease the number of transfusions received. For infants 1,001-1,250g ...
What is the current status of trial NCT01203514?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 318 participants. The study started on 1997-08. Estimated completion is 2000-08.
What interventions are being tested in trial NCT01203514?
The interventions under investigation include: Sham Comparator (OTHER), Erythropoietin (DRUG).
Who is sponsoring clinical trial NCT01203514?
This trial is sponsored by NICHD Neonatal Research Network, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01203514's enrollment target sits among peer trials
318 153rd of 2000 higher than 1,846 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05488340 · 318 participants · Phase 2
A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
- NCT05675735 · 318 participants · NA
Leveraging Regulatory Flexibility for Methadone Take-Home Dosing to Improve Retention in Treatment for Opioid Use Disorder
- NCT05895786 · 318 participants · Phase 3
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
- NCT06051617 · 318 participants · Phase 3
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia